Issue 6, 2022

Pt(iv) antitumor prodrugs: dogmas, paradigms, and realities

Abstract

Platinum(II)-based drugs are widely used for the treatment of solid tumors, especially in combination protocols. Severe side effects and occurrence of resistance are the major limitations to their clinical use. To overcome these drawbacks, a plethora of Pt(IV) derivatives, acting as anticancer prodrugs, have been designed, synthesized and preclinically (often only in vitro) tested. Here, we summarize the recent progress in the development and understanding of the chemical properties and biochemical features of these Pt(IV) prodrugs, especially those containing bioactive molecules as axial ligands, acting as multi-functional agents. Even though no such prodrugs have been yet approved for clinical use, many show encouraging pharmacological profiles. Thus, a better understanding of their features is a promising approach towards improving the available Pt-based anticancer agents.

Graphical abstract: Pt(iv) antitumor prodrugs: dogmas, paradigms, and realities

Article information

Article type
Perspective
Submitted
16 Nov. 2021
Accepted
24 Dec. 2021
First published
27 Dec. 2021

Dalton Trans., 2022,51, 2121-2134

Pt(IV) antitumor prodrugs: dogmas, paradigms, and realities

M. Ravera, E. Gabano, M. J. McGlinchey and D. Osella, Dalton Trans., 2022, 51, 2121 DOI: 10.1039/D1DT03886A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements